Schweiz
bioMérieux Introduces Revolutionary LockSure® Plate Technology
07 September, 2010
Lab Informatics Expert Joins bioMérieux
19 Juli, 2010
A world leader in in vitro diagnostics, bioMérieux today announced the appointment of Jacques L. Baudin as Vice President, Commercial Operations Information Technology.
Data from Clinical Studies of bioTheranostics’ CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting*
06 Juni, 2010
bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company’s CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.
bioMérieux Showcases Myla™ at ASM 2010: New Informatics Solution to Transform the Microbiology Laboratory
25 Mai, 2010
Innovative solution optimizes laboratory workflow and clinical information management. A world leader in in vitro diagnostics, bioMérieux presented Myla™, a revolutionary new middleware solution to improve connectivity, laboratory workflow and information management, at the 110th General Meeting of the American Society for Microbiology (ASM) in San Diego. Part of bioMérieux’s FMLA™* solutions and services, Myla is an intelligent browser-based application that consolidates and manages microbiology data generated from a variety of sources and converts these data into actionable information for treatment decisions. Designed to transform the way that laboratory managers and technicians work, Myla recaptures time spent on information retrieval and reporting activities through a simple dashboard-based user interface that provides full control of lab workflow.
Shimadzu and bioMérieux Enter into Partnership for Mass Spectrometry Applications in Microbiology
21 Mai, 2010
Shimadzu and bioMérieux announce today that they have entered into a partnership to commercialize a mass spectrometry system for bacterial identification in microbiology laboratories. bioMérieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt their linear MALDI-TOF* mass spectrometry technology for optimized integration into the microbiology laboratory workflow. This new solution is planned for commercialization by bioMérieux in 2010, together with the microbial database acquired from AnagnosTec.
bioMérieux and GlaxoSmithKline Enter into Alliance to Develop Molecular Theranostic Test for Cancer Treatment Selection
10 Mai, 2010
bioMérieux and GlaxoSmithKline (GSK) have signed an agreement to develop a novel molecular test for cancer. In this new collaboration, the two companies will develop a theranostic test to aid oncologists in choosing the appropriate treatment for metastatic melanoma (skin cancer).